Bremelanotide Research: Desire, Distress and the RECONNECT Trials

Bremelanotide offers a useful example of why a clinical trial cannot be reduced to a single claim that a peptide “works”. The relevant questions are what changed, how it was measured, who was studied and what trade-offs accompanied the result. Its clinical programme examined several outcomes that sound similar in everyday conversation but answer different research questions.

What the earlier trial measured

A 2016 randomised, placebo-controlled study investigated bremelanotide in premenopausal women with female sexual dysfunction. The 12-week study included 397 randomised participants, with efficacy data available for 327. Its primary endpoint was the change in satisfying sexual events per month. In the pooled higher-treatment groups, the mean increase was 0.7 events, compared with 0.2 with placebo. Nausea, flushing and headache were reported adverse events. [1]

This is an absolute difference of approximately half an event per month between the reported mean changes. It should not be described as a guarantee that any particular participant experienced an additional event. Group averages summarise a distribution of responses, and they do not show how much a particular person values a change. The earlier population also included arousal disorder, low-desire disorder, or both, so its scope deserves attention when comparing later studies. [1]

RECONNECT asked about desire and distress

The two RECONNECT phase 3 trials used randomisation, double blinding and placebo control over 24 weeks. They randomised 1,267 premenopausal women with hypoactive sexual desire disorder, or HSDD; 1,202 were included in the modified intention-to-treat efficacy population. The two primary measures concerned sexual desire and distress about low desire. Both improved relative to placebo. [2]

These are patient-reported outcomes, not hormone measurements or laboratory biomarkers. That does not make them unimportant: experiences such as desire and distress are relevant to the condition being studied. It does mean that the questionnaire, its scoring direction and the size of the treatment difference need to stay attached to the finding. A statistically significant score change is not automatically a percentage improvement in a person's overall sexual wellbeing.

The event-count result was negative

The phase 3 studies did not demonstrate a significant treatment difference in the change in satisfying sexual-event counts. That secondary outcome must remain visible beside the positive primary findings. Most participants were white and enrolled at US sites, and withdrawal rates were higher with bremelanotide. These features limit how broadly the results can be applied. [2]

There is no logical requirement for all these endpoints to move together. Someone's reported interest, distress and number of events can differ. Conversely, a positive result on one measure cannot be borrowed to advertise success on a different measure that did not improve. Reading the prespecified endpoints separately avoids both dismissing a real finding and exaggerating its scope.

Approval applies to a defined medicine and population

The US prescribing information for Vyleesi, the bremelanotide injection formulation initially approved in 2019, specifies acquired, generalised HSDD in premenopausal women. The low desire must not be explained by another medical or psychiatric condition, relationship problems, or medication or drug effects. The label does not indicate it for men, postmenopausal women or sexual-performance enhancement. [3]

The same information lists uncontrolled hypertension and known cardiovascular disease as contraindications. It warns about temporary blood-pressure increases, reduced heart rate and focal hyperpigmentation. Nausea occurred in 40% of treated participants in the phase 3 placebo-controlled trials and led to premature discontinuation in 8%. These figures show why efficacy and tolerability require separate consideration. [3]

How to use this evidence responsibly

A reader evaluating a new bremelanotide claim can ask whether it names the population, distinguishes questionnaire scores from event counts, and describes adverse effects alongside benefits. A headline that omits the negative endpoint provides an incomplete account, even if its positive statement is technically accurate. Neither the early study nor RECONNECT establishes that every product carrying the compound name is clinically interchangeable.

Bali Peptide Lab is a commercial research-product supplier. This article discusses clinical literature for education; it does not recommend personal treatment or provide administration instructions. Approval of Vyleesi does not extend to research-labelled materials, other formulations or every jurisdiction. Individual clinical suitability requires assessment by a qualified healthcare professional.